Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP.

1st Department of Medicine Hematology Charles University General Hospital and 1st Faculty of Medicine Nové Město Czech Republic

Azienda Ospedaliera Spedali Civili di Brescia Brescia Italy

Blood and Marrow Transplant Program Stanford Cancer Center Stanford CA

Calvary Mater Newcastle Hospital Waratah NSW Australia

Centre for Lymphoid Cancer and Division of Medical Oncology British Columbia Cancer Vancouver BC Canada

Department of Haematology Odense University Hospital Odense Denmark

Department of Hematology and Medical Oncology Universitätsmedizin Göttingen Göttingen Germany

Department of Hematology Université de Lille Centre Hospitalier Universitaire Lille ULR 7365 Groupe de Recherche sur les formes Injectables et les Technologies Associées Lille France

Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

Division of Cancer Sciences Faculty of Biology Medicine and Health University of Manchester Manchester United Kingdom

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation Department of Medical Oncology Thomas Jefferson University Philadelphia PA

E Couric Cancer Center University of Virginia Charlottesville Virginia and TG Therapeutics New York NY

Hematology Division National Cancer Center Hospital Tokyo Japan

Institut Catala D'oncologia L'Hospitalet de Llobregat Barcelona Spain

Kite Pharma Santa Monica CA

MD Anderson Cancer Center University of Texas Houston TX

Memorial Sloan Kettering Cancer Center New York NY

Millennium Pharmaceuticals Inc Cambridge MA

National Institutes of Health and Research Biomedical Research Center Manchester Academic Health Sciences Christie Hospital National Health Service Foundation Trust Manchester United Kingdom

NewYork Presbyterian Columbia University Irving Medical Center New York NY

Scientific Institute for Research Hospitalization and Healthcare Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Università degli Studi Bologna Italy

Seagen Inc Bothell WA

University of Washington Medical Center Seattle WA

See more in PubMed

Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9(7):717–720. PubMed

d’Amore F, Gaulard P, Trümper L, et al. ESMO Guidelines Committee Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v108–v115. PubMed

Horwitz SM, Zelenetz AD, Gordon LI, et al. NCCN Guidelines insights: non-Hodgkin’s lymphomas, version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067–1079. PubMed

Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. PubMed

Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–1475. PubMed

Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159–166. PubMed

Savage KJ, Harris NL, Vose JM, et al. International Peripheral T-Cell Lymphoma Project ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–5504. PubMed

Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983–2986. PubMed

Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81–e82. PubMed PMC

Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2008;20081:280–288. PubMed

d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–3099. PubMed

Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31(25):3100–3109. PubMed PMC

Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211–2217. PubMed PMC

Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715–723. [published correction appears in Ann Oncol. 2021;32(7):945] PubMed

Horwitz S, O’Connor OA, Pro B, et al. ECHELON-2 Study Group Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240. PubMed PMC

Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288–298. PubMed PMC

Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. PubMed

Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017;130(4):554–557. PubMed PMC

Hapgood G, Ben-Neriah S, Mottok A, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186(3):e28–e31. PubMed PMC

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

See more in PubMed

ClinicalTrials.gov
NCT01777152